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A B S T R A C T   
Humans are simultaneously exposed to complex mixtures of chemicals with limited knowledge on potential 
health effects, therefore improved tools for assessing these mixtures are needed. As part of the Human Bio-
monitoring for Europe (HBM4EU) Project, we aimed to examine the combined biological activity of chemical 
mixtures extracted from human placentas using one in vivo and four in vitro bioassays, also known as biomarkers 
of combined effect. Relevant endocrine activities (proliferative and/or reporter gene assays) and four endpoints 
were tested: the estrogen receptor (ER), androgen receptor (AR), and aryl hydrocarbon receptor (AhR) activities, 
as well as thyroid hormone (TH) signaling. Correlations among bioassays and their functional shapes were 
evaluated. Results showed that all placental extracts agonized or antagonized at least three of the above-
mentioned endpoints. Most placentas induced ER-mediated transactivation and ER-dependent cell proliferation, 
together with a strong inhibition of TH signaling and the AR transactivity; while the induction of the AhR was 
found in only one placental extract. The effects in the two estrogenic bioassays were positively and significantly 
correlated and the AR-antagonism activity showed a positive borderline-significant correlation with both es-
trogenic bioassay activities. However, the in vivo anti-thyroid activities of placental extracts were not correlated 
with any of the tested in vitro assays. Findings highlight the importance of comprehensively mapping the bio-
logical effects of “real-world” chemical mixtures present in human samples, through a battery of in vitro and in 
vivo bioassays. This approach should be a complementary tool for epidemiological studies to further elucidate the 
combined biological fingerprint triggered by chemical mixtures.   
1. Introduction 
Humans are exposed to hundreds of environmental chemicals at low 
doses [1]. Many of these environmental pollutants have been detected in 
different human matrices such as urine, serum and placenta [2–5] and 
constitute an important part of the human exposome [6]. Appropriate 
risk assessment of chemical mixtures with human relevance relies on 
accurately characterizing the mixture composition and the available 
toxicological information on the constituents of the mixture. However, 
for many chemicals the information of both, exposure and toxicity is 
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lacking [7]. Thus, predicting the effects of exposure to chemical mix-
tures in human populations is one of the main challenges of current 
toxicology and environmental epidemiology [8,9]. 
Epidemiologic investigations have traditionally followed a one- 
compound-at-a-time strategy to assess possible associations between 
environmental chemical exposure and adverse health effects. A disad-
vantage of this approach is that it ignores additive effects or synergistic 
and/or antagonistic interactions with other chemicals [10]. To address 
this challenge, complementary statistical multi-pollutant models to 
disentangle independent associations among several co-exposures have 
been applied [11,12]. However, these valuable statistical approaches 
also present inherent deficiencies and limitations, for example, that they 
only evaluate a limited number of chemicals with pre-existing toxico-
logical knowledge, probably underestimating the effects of exposure to 
real-life mixtures. 
To examine the effects of “real-world’’ mixtures present in humans, 
including both known and unknown environmental chemicals, alter-
native approaches are needed. Chromatographic methods are of great 
utility since they allow the isolation of fractions containing compounds 
with similar physicochemical characteristics, separating them from 
endogenous hormones [13,14]. The isolated fractions can be tested in a 
battery of in vitro assays covering different molecular initiating events 
and/or molecular targets, enabling the characterization of various bio-
logical effects exerted by the chemical mixture. This approach has been 
successfully applied in the ecotoxicological field to monitor changes in 
water biological activity without the need to screen for hundreds of 
chemicals, and/or to identify emerging pollutants [15–17]. Likewise, 
human matrices can be used to evaluate the combined effect of chemical 
mixtures in epidemiologic studies, and identify emerging exposures. 
However, this research field is still immature and awaits further explo-
ration [18]. 
As reported by authors of the EU-project SOLUTIONS, there is a need 
to balance the way to deal with mixture exposures and their combined 
effects, since single-chemical exposure approaches tend to ignore data 
gaps (i.e., missing contaminants), while effect-based approaches may 
lead to increased uncertainty factors such as the need to further develop 
suspect and non-targeted screening techniques [19]. Thus, combining 
both approaches may provide the best results. Previous epidemiological 
studies have shown that it is possible to obtain chemical fractions from 
human matrices in which, for example, the most persistent and lipo-
philic contaminants, without the presence of endogenous hormones, are 
isolated by various analytical techniques [20–24]. In this context, bio-
assays testing the combined biological effect of chemical fractions iso-
lated from human samples are usually referred to as “biomarkers of 
combined activity’’, “biomarkers of combined effect”, “biomarkers of ex 
vivo hormonal activity”, and/or “biomarkers of combined internal 
exposure” [20,25,26]. The advantage of this approach is that the bio-
logical effect is measured taking into account all bioactive chemicals as 
well as plausible interactions among them that may lead to synergistic or 
antagonistic mixture effects. The total joint effect of human extracts is 
hypothesized to provide a more holistic strategy to address the true 
cause of the disease provided that the adverse outcome is related to a 
specific receptor activity or pathway. 
In this regard, among the studies performed on human samples, some 
effect endpoints have included estrogenic and antiandrogenic activities. 
The so-called “total effective xenoestrogen burden’’ (TEXB) has been 
implemented in several epidemiological studies for endocrine-related 
diseases such as male urogenital malformations and breast cancer [27, 
28], by assessing the combined in vitro estrogenic activity of chemical 
mixtures extracted from different human matrices including serum, 
placenta and adipose tissue [13,23,29]. A higher total effective xeno-
biotic burden of anti-androgens (TEXB-AA), which evaluates the com-
bined anti-androgenic activity exerted by mixtures of pollutants present 
in human placental extracts, was also associated with an increased risk 
of urogenital malformations in boys [20]. Other signaling pathways, 
including the aryl hydrocarbon receptor (AhR) and thyroid function, 
have also been explored, but to a lesser extent compared with the 
abovementioned endpoints [18]. 
There are some gaps in knowledge associated with the use of in vitro 
and in vivo biomarkers of combined activity that need to be addressed, 
such as the standardization across laboratories regarding the procedures 
performed for the correct execution of bioassays and comparisons 
among a panel of different bioassays using the same biological matrix. 
Therefore, the main objective of this study was to assess, characterize 
and compare the combined biological effect of chemical mixtures 
extracted from the same human placentas by quantifying the signal 
elicited in five bioassays, covering relevant endocrine activities (in vitro 
proliferative and reporter gene assays for estrogen, androgen and aryl- 
hydrocarbon, and in vivo thyroid function). 
2. Materials and methods 
2.1. Study population 
Twenty-five placenta samples were randomly selected among those 
kept at the biobank of the San Cecilio University Hospital (Granada, 
Spain) from healthy women participating in the INMA -INfancia y 
MedioAmbiente (Environment and Childhood)-, Granada birth cohort 
study, recruited from October 2000 to July 2002 [30]. Participants for 
which a limited quantity of placenta was available were excluded before 
the random selection. Characteristics of the study population were ob-
tained from medical records and validated questionnaires [27]. Pla-
centas were collected at time of delivery, weighed without fetal 
membranes/maternal decidua, and frozen at -80 ◦C. The INMA study 
followed the principles of the declaration of Helsinki and was approved 
by the Ethics Committee of San Cecilio University Hospital. All partici-
pants signed the informed consent allowing the use of biological samples 
for environmental research purposes. 
2.2. Study design 
This work aimed to address the combined effects of “real-world” 
chemical mixtures of persistent and lipophilic chemicals present in 
human placenta samples using several bioassays, taking into account all 
bioactive chemicals as well as plausible interactions among them. 
Placental homogenates were extracted using a validated semi- 
preparative chromatographic separation protocol [24,29] at the facil-
ities of the University of Granada (UGR), Spain. Afterwards, dried 
high-performance liquid chromatography (HPLC) fractions were sent on 
dry ice to the participating institutions in order to conduct specific 
bioassays. Five bioassays were performed: the E-Screen, conducted at 
the University of Granada (UGR) Spain; the estrogen receptor (ER) re-
porter gene assay, performed at the Aarhus University (AU), Denmark; 
the androgen receptor (AR) and aryl hydrocarbon receptor (AhR) re-
porter gene assays, tested at the Technical University of Denmark (DTU); 
and the Xenopus eleutheroembryonic thyroid assay (XETA), tested at the 
National Center of Scientific Research (CNRS) in France (Table 1). 
Table 1 
Bioassays and institutions in which they were performed.  
Laboratory Biological 
material 
Bioassays (Biomarkers of combined effect) 
UGR (Spain) 24 α-Fractions E-Screen. Estrogenic proliferative effect. 
AU (Denmark) 24 α-Fractions ER reporter gene assay. ER induction effect. 
DTU (Denmark) 24 α-Fractions AR reporter gene assay. Anti-androgenic effect. 
AhR reporter gene assay. Aryl Hydrocarbon 
receptor induction. 
CNRS (France) 24 α-Fractions Xenopus eleutheroembryonic thyroid assay. 
Thyroid hormone disruption. 
AU: Aarhus University; CNRS: National Center of Scientific Research; DTU: 
Technical University of Denmark; UGR: University of Granada. 
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2.3. Placenta extraction protocol 
To ensure the representativity of the whole placenta tissue, half of 
the placenta was cut, defrosted, placed in the glass container of a mixer 
(Büchi Mixer B-400 Büchi Laboratories AG, Flawil, Switzerland) and 
homogenized (Fig. 1.A). Placental homogenates were extracted 
following a previously validated semipreparative HPLC protocol [27,29] 
to efficiently separate organo-halogenated lipophilic chemicals from 
endogenous hormones and more polar compounds, using a 
normal-phase column and a gradient with two mobile phases. Of the 
initial 25 placentas, one was excluded due to technical issues during 
extraction. The placental homogenization and the semi-preparative 
HPLC extraction protocol are graphically summarized in Fig. 1. 
Briefly, 3 g of placenta homogenate was split in two 5 mL Falcon 
tubes with 1.5 g each. Then, 1.5 mL of distilled water was added into the 
tubes, which were vortexed for 1 min (Fig. 1.B). Successively, the 
mixture was extracted by adding 3 mL of ethyl acetate and vortex- 
shaked again for 10 min. Afterwards, the mixture was centrifuged for 
10 min at 4050 × g. The two supernatants were pooled in a clean glass 
vial, and the extract was evaporated to dryness at room temperature 
under a nitrogen stream. The dried extract was dissolved with hexane 
(700 μL) and dried once more under nitrogen stream. Then it was dis-
solved in 400 μL of hexane and injected twice (200 μL) into a column to 
undergo preparative HPLC. The placental extract was eluted by a spe-
cific gradient of two mobile phases: n-hexane (phase A) and n-hexane: 
methanol:2-isopropanol (40:45:15)(v/v) (phase B) at a flow rate of 1.0 
mL/min. Specifically, the α-fraction represents the first 11 min of elution 
of the chromatographic run. The whole process was repeated 5 times 
and the obtained α-fractions were sent on dry ice to each participant 
laboratory (Fig. 1.B). The available knowledge to date has shown the 
presence of common persistent and lipophilic pollutants in the α-frac-
tion, and the absence of steroid endogenous hormones [13,31,32]. Ex-
amples of chemical compounds present in different minutes of elution of 
the α-fraction can be consulted in Table S1 of the Supplementary 
Material. 
2.4. Bioassays 
Each laboratory reconstituted the dried α-fractions and made specific 
dilutions to be tested following the requirements of each specific 
bioassay (e.g. sensitivity, range and cytotoxicity threshold). To facilitate 
the comparison among bioassays, the concentrations of placental 
α-fractions tested were expressed as mg of placenta extracted per well 
volume in mL (mgplacenta/mL). The corresponding calculations for each 
bioassay are explained in Table S2 of the Supplementary Material. 
2.4.1. E-Screen 
MCF-7 cells were used to assess the proliferative effect induced by 
placental α-fractions as described previously [27]. Cells were seeded at a 
density of 4 × 103 cells/well in 96-well plates (obtained by Falcon®, 
VWR International Eurolab, Barcelona, Spain) in culturing medium 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) with phenol 
red supplemented with 10 % fetal bovine serum (FBS) (Gibco, Invi-
trogen, Spain) and left at 37 ◦C with 5% CO2. After 24 h, culturing 
medium was replaced with experimental medium, consisting of phenol 
red-free DMEM supplemented with 10 % dextran-coated charcoal--
stripped FBS (DCCS-FBS) (Gibco, Invitrogen, Spain). Dried α-fractions 
were reconstituted in 1 mL of experimental medium, vigorously shaken, 
left to rest for 30 min, filtered through a 0.22 μm filter, and diluted 1, 5 
and 10 times, and tested in triplicates. Each well plate included 150 μL of 
experimental medium together with 50 μL of placental α-fractions. Di-
lutions x1, x5 and x10 corresponded to 750 mgplacenta/mL, 150 mgpla-
centa/mL and 75 mgplacenta/mL, respectively (Table S2). After 6 days of 
exposure, cells were fixed, stained with sulforhodamine B (Sigma-Al-
drich, MO, USA) and the solubilized bound dye was read at 492 nm in a 
Titertek Multiscan plate reader (Flow, Irvine, CA, USA). 17β-estradiol 
was tested as a positive control at concentrations of 0.1 pM-1000 pM. 
Experimental medium was used as negative control. 
2.4.2. Estrogen receptor (ER) reporter gene assay 
The activation of ERs by placental α-fractions was evaluated with the 
stably transfected human breast adenocarcinoma MVLN cells carrying 
the estrogen response element luciferase reporter vector (provided by M. 
Pons, France). The procedure followed was previously described by 
Bjerregaard-Olesen and colleagues [33]. Briefly, cells were seeded at a 
density of 8.5 × 104 cells/well in 96-well plates with culture medium 
that included phenol red-free DMEM (LONZA, Belgium) supplemented 
with 1% DCCS-FBS (HyClone, Belgium), 6 μg/L insulin (Sigma, USA), 64 
mg/L hexamycin (Sandoz, Denmark), 4 mM glutamine (Sigma,USA), 
and 20 mM HEPES (Gibco, UK), and were left to incubate at 37 ◦C with 
5% CO2 overnight. The experimental medium consisted on phenol 
red-free DMEM (LONZA, Belgium) containing 0.5 % DCCS-FBS. Dried 
α-fractions were reconstituted in 44 μL EtOH:H2O:DMSO (50:40:10, 
V/V/V) and from this reconstituted 44 μL, we used 20 μL that were 
subsequently diluted in experimental medium 55, 275, and 550 times. 
Successively, 100 μL of these diluted extracts were added into the well 
Fig. 1. A) Placental homogenization. After 
weighing the placenta (1), it was cut in half by 
using a template (2). One half was homogenized 
and the rest was kept at -80 ◦C. The homogenate 
was split into 25 g aliquots (3). From a 25 g 
homogenate, a 3 g aliquot was taken for the 
chemical extraction (4). B) Chemical extraction 
and chromatographic separation protocol. The 
α-fraction corresponds to the first 11 min of 
semi-preparative HPLC chromatographic 
elution, which has been previously shown to 
contain the most persistent and lipophilic com-
pounds, while avoiding endogenous hormones.   
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and analyzed in triplicate. The dilutions 55, 275 and 550 correspond to 
1240 mgplacenta/mL, 248mgplacenta/mL and 124 mgplacenta/mL, respec-
tively (Table S2). After 24 h of exposure, the luciferase activity was 
measured with automatic injection of luciferase substrate (D-luciferin, 
free acid, Molecular Probes, L2911, Invitrogen) using a LUMIstar 
luminometer (BMG Labtech, RAMCON). Cell protein levels were quan-
tified to correct for differences in cell numbers in the well. Protein was 
quantified by fluorometric measurements using a WALLAC Victor2 
(Perkin Elmer). Cell viability was assessed visually at the microscope, 
and for cells with visual cytotoxicity, low protein levels were also 
observed. As a quality control, a dose-dependent 17β-estradiol curve at 
1.5 pM-300 pM was tested in parallel. 
2.4.3. Androgen receptor (AR) reporter gene assay 
The AR reporter gene assay was performed as previously described 
[34] with few modifications, to evaluate the anti-androgenic activity of 
placental α-fractions. The AR-EcoScreen cell line (JCRB Cell Bank, cat. 
No. JCRB1328), cultured in DMEM-F12 without phenol red (Life Tech-
nologies, CA, USA) and supplemented with 5% DCCS-FBS (Life Tech-
nologies, CA, USA), 50 units/mL penicillin, 50 μg/mL streptomycin (Life 
Technologies, CA, USA), 200 μg/mL zeocin (Invivogen, CA, USA), and 
100 μg/mL hygromycin (Invitrogen, CA, USA), was seeded at a density 
of 0.9 × 104 cells/well in 96-well plates (Costar, Corning, USA). The 
experimental medium consisted of DMEM-F12 without phenol red 
supplemented with penicillin/streptomicin (but without zeocin or 
hygromycin), and 5% DCCS-FBS (Sigma Aldrich, MO, USA). Before 
exposure was initiated, plates were left in the incubator for 24 h at 37 ◦C 
with 5% CO2. Dried α-fractions were reconstituted in 400 μL of hexane, 
which was split in four glass vials and left to evaporate until dryness. 
Evaporated α-fractions were reconstituted with 250 μL of experimental 
medium, left to rest for 30 min, filtered with a 0.22 μm filter and diluted 
60-, 180-, and 600 times. Successively, 50 μL of diluted fractions 
together with 150 μL of experimental medium were added into wells. 
Dilutions 60, 180 and 600 corresponded to 12.5 mgplacenta/mL, 4.2 
mgplacenta/mL and 1.25 mgplacenta/mL (Table S2). All treatments, 
including controls were co-treated with 0.1 nM metribolone (R1881) 
(PerkinElmer, MA, USA), a known inductor of the AR activity. After ~20 
h of exposure, 100 μL Dual-Glo® Firefly Luciferase Reagent, prepared 
according to manufacturer’s protocol (Dual-Glo® Luciferase Assay 
System, Promega, USA) was added to wells, and plates were left on a 
shaker table for 10 min. Then, the luminescence was measured using a 
BioOrbit, Galaxy luminometer to assess AR activity. Successively, 50 μL 
of Dual-Glo® Stop & Glo® reagent was added to wells, plates were left 
on shaker table for 15 min, and luminescence was measured (BioOrbit, 
Galaxy) to assess cell viability, measured by the stably transfected 
construct of Renilla luciferase. This assay provides a direct measure of 
cytotoxicity in the cells. The assay was performed in three independent 
experiments with technical triplicates for each treatment within the 
experiment. Hydroxyflutamide (OHF), a known antagonist of AR ac-
tivity, was used as quality control and tested in concentrations ranging 
from 1 × 103-5000 × 103 pM in all experiments. 
2.4.4. Aryl hydrocarbon receptor (AhR-CALUX) reporter gene assay 
The induction of AhR is known for leading to the transcription of 
metabolizing enzymes [35]. To evaluate the activation of the AhR re-
ceptor, a stably transfected rat hepatoma (H4IIE-CALUX) cell line was 
used [36]. Briefly, 2.2 × 104 cells/well were seeded in 96-well plates and 
incubated for ~22 h at 37 ◦C with 5% CO2 in culture medium, which 
consisted of minimum essential medium α (MEM α) supplemented with 
5% FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 0.25 
μg/mL Gibco Amphotericin B (Life Technologies). The FBS content was 
reduced to 1% during experiments (experimental medium). Dried 
α-fractions were reconstituted in 400 μL of hexane, split into four glass 
vials, and left to evaporate until dryness. Evaporated α-fractions were 
reconstituted in 250 μL of experimental medium, left to rest for 30 min, 
filtered through a 0.22 μm filter, and diluted 100-, 300-, and 1000 times. 
Successively, 50 μL of diluted fractions together with 150 μL of experi-
mental medium were added into wells and tested in two independent 
experiments. Dilutions corresponded to 7.5 mgplacenta/mL, 2.5 mgpla-
centa/mL and 0.75 mgplacenta/mL, respectively (Table S2). After ~22 h of 
exposure, cells were lysed and the luminescence was measured by the 
addition of 40 μL luciferin solution containing 0.5 mM luciferin and 0.5 
mM ATP in lysis buffer. Cell viability was tested following the protocol 
above, but seeding only 1.1 × 104 cells/well. At assay termination, 
medium was removed and 50 μL of fresh medium was added. 3-(4, 
5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
was added leading to a final concentration of 0.45 mg/mL and incubated 
for 1.5 h. Afterwards, medium was removed and 50 μL/well isopropanol 
was added. Plates were left on a shaker table for 5 min after which 
absorbance was measured. 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
was used as positive control and tested in concentrations ranging from 
0.5 pM to 3000 pM. 
2.4.5. Xenopus eleutheroembryonic thyroid assay (XETA) 
The XETA is a miniaturized and relatively high throughput in vivo 
assay to detect disruption of thyroid hormone (TH) signaling through 
variations in the fluorescence emitted by transgenic tadpoles [37]. To 
assess whether placental α-fractions inhibit or activate TH signaling 
during embryonic stages, Nieuwkood and Faber (NF) stage 45 Xenopus 
laevis tadpoles (1 week old) from the Tg(thibz:eGFP) line were used, as 
previously described [38]. The construct contains the promoter of the 
TH- sensitive TH/bZIP promoter coupled to a Green Fluorescent Protein 
(GFP) reporter gene to capture disruption of TH signaling that may 
involve multiple points of regulation of the thyroid axis. Briefly, dried 
α-fractions were reconstituted in 16 μL of DMSO and 400 μL of Evian 
water. Reconstituted α-fractions were then split into two parts of 208 μL 
each which were added to wells and tested in duplicates within four 
independent experiments. Each well was completed with experimental 
medium up to 8 mL, reaching a concentration equivalent to 187.5 
mgplacenta/mL. Fifteen tadpoles per well were placed in 6-well-plates 
(TPP Switzerland) containing 8 mL of either control solvent (DMSO) 
in Evian water, thyroid hormone triiodothyronine T3 (5 nM), or 
α-fractions spiked with T3 (5 nM). DMSO (0.01 %) was present in all 
treatments and plates were placed at 23 ◦C. After 72 h of exposure, 
tadpoles were anesthetized and color images of each tadpole manually 
positioned in a well of a 96-well plate were acquired using an Olympus 
AX-70 binocular equipped with long pass GFP filters and a Q-Imaging 
Exi Aqa camera (25x objective, and 3 s exposure). QC Capture pro 
(QImaging) software was used for image acquisitions and quantifica-
tions were carried out using ImageJ. Quantifications were carried out in 
a region of interest (ROI) containing the whole head area while 
excluding the non-specific auto-fluorescence emitted from the gut area 
(Figure S1, Supplementary Material). 
2.5. Data handling and statistical analysis 
All bioassay data were normalized to the mean of solvent plate 
control(s). If more than one independent experiment was conducted, the 
means from independent experiments were pooled. Normal distribution 
analysis was conducted (D’Agostino & Pearsons omnibus test). XETA 
results were not normally distributed, and the difference between 
experimental samples and controls was performed using the Kruskal- 
Wallis test (Dunn’s post hoc test). For in vitro data, and based on the 
number of replicates for each sample, the distribution could not be 
evaluated. Therefore, classification of samples as positive in the bio-
assays was based on cut-off values calculated from the limit of detection 
(LOD). For the E-Screen, LOD value has previously been standardized to 
>2.0 [39]; for the remaining agonist assays, LOD was defined as 1 plus 3 
times the standard deviation (SD) of the vehicle control, and for the 
antagonist assays, the LOD was calculated as 1 minus 3 times the SD of 
the vehicle control. Positive controls were fitted to a four-parameter 
non-linear regression curve with the vehicle controls constrained to 1 
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and in the case of inhibitors, the lower limit constrained to >0. The 
maximum efficacy (Emax) obtained for the positive controls or α-frac-
tions was defined as the observed maximum change compared to the 
vehicle control, and calculated as the percentage difference between the 
highest fold change reached minus that of the vehicle control (set to 1). 
All data processing was performed in GraphPad Prism 8.1. 
To assess correlation between bioassay responses, all samples were 
normalized to vehicle controls constrained to 1, and then fold-change 
values were expressed as percentages, in order to represent values for 
both agonist and antagonist effects. Firstly, Pearson correlation co-
efficients were calculated between the effect magnitude (percentage of 
biological activity) of the different bioassays. Secondly, and to assess the 
shape of correlations within relevant findings, we performed linear 
regression models categorizing the independent variable into tertiles. 
Thus, placentas eliciting the lowest signals in the bioassay of interest 
were categorized in the first tertile (T1), while placentas with the 
highest signal were located in the third tertile (T3). The coefficient of 
determination (r2) was calculated for each regression to estimate the 
proportion of the variance in the dependent variable that is predicted by 
the independent variable. All correlations between biomarkers were 
conducted using the SPSS v24.0 (IBM, Chicago, IL), significance level 
was set at p ≤ 0.05 and borderline significance was set at p ≤ 0.1. 
3. Results 
3.1. Study population 
In this study, 44 % of the newborns were boys and 56 % were girls; 
mean (SD) gestational age was 39 (1.2) weeks. Mean (SD) head 
circumference was 34.4 (1.7) cm, birth weight and birth length were 
3.35 (0.4) kg and 50.94 (2.1) cm, respectively. No infant was born 
preterm (<37 week) or with low birth weight (<2.5 kg). Mean (SD) age, 
pre-pregnancy weight and height of mothers was 30 (4.9) years, 68.1 
(15.9) kg and 1.65 (0.1) m, respectively; and with a mean (SD) pre- 
pregnancy BMI of 24.9 (4.5) kg/m2. Half of mothers (48 %) received 
higher education (university studies/professional formation), 84 % did 
not consume tobacco and 52 % were primiparous. 
3.2. Positive controls and cut-off values 
Results obtained for positive controls known to induce or inhibit the 
tested endpoints are shown in Fig. 2. The half maximal effect concen-
tration (EC50) and the half maximal inhibitory concentration (IC50)- 
values were determined based on a 4-parameter curve fit. Briefly, EC50 
values were 0.02 nM (17β-estradiol), 0.03 nM (17β-estradiol), 0.05 nM 
(metribolone) and 0.04 nM (2,3,7,8-tetrachlorodibenzo-p-dioxin) for 
the E-Screen, and the ER, AR, and AhR reporter gene assays, respec-
tively. The IC50 value was 0.79 nM (hydroxyflutamide) in the AR re-
porter gene assay. Maximum efficacies for positive controls tested in 
each in vitro assay were as follows, E-Screen: 580 %, ER: 213 %, AR: 694 
% metribolone and 66 % hydroxyflutamide and AhR: 904 % (Fig. 2). 
Cut-off values to classify a placenta extract as positive were based on 
LODs (illustrated with dotted line in Fig. 3). For E-screen, ER and AhR 
agonism, cut-off values were set to >2.0 [39], >1.5 and >1.8-fold 
change, respectively. For AR antagonism, the cut-off value was set to 
<0.8-fold change. 
3.3. Combined biological activities exerted by placental α-fractions 
3.3.1. Estrogenic activity 
All twenty-four placental α-fractions elicited a concentration 
dependent proliferative effect (PE) at varying degrees in the E-Screen 
Fig. 2. Concentration-response curves and 
standard deviations (SD) for positive controls 
tested in in vitro bioassays. (A) 17β-estradiol 
(E2) for the E-Screen assay. (B) E2 for the ER 
transactivation assay. (C) Hydroxyflutamide 
(OHF) and metribolone (R1881) for the AR re-
porter gene assay. (D)2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD) for the AhR 
reporter gene assay. Data points represent 
means from 1 (Fig. A and, B), 2 (Fig. D) or 3 
(Fig. C) independent experiments. Diamonds 
point out the EC50/IC50 values.   
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assay (Fig. 3.A), and all α-fractions were above the cut-off value (dotted 
line, Fig. 3.A) at the highest concentration tested. Samples led to 
maximal effects at 750 mgplacenta/mL, with 14 out of 24 samples 
reaching a proliferation efficacy above 450 %. 
In the ER transactivation assay, all α-fractions at both concentrations 
of 124 and 248 mgplacenta/mL, were above the cut-off value, with the 
exception of placentas # 2, 21 and 25 (dotted line Fig. 3.B). Notwith-
standing, at least one of the concentrations tested for placentas # 2 and 
25 were above the cut-off value and most placentas (23 out of 24) were 
thus deemed positive for ER activity (Table 2). Most placental α-frac-
tions tested at the highest concentration (1240 mgplacenta/mL) compro-
mised cell viability, except α-fraction # 2. Fractions tested at 124 and 
248 mgplacenta/mL induced increased ER transactivity compared to the 
negative control, which appeared concentration dependent for placental 
α-fractions # 5, 7 and 14. More than half of the α-fractions led to an 
efficacy above 200 %, with the exception of fractions # 2, 7, 12, 15, 16, 
20, 22, 23, 24, and 25. 
3.3.2. Anti-androgenic activity 
Most α-fractions showed an inhibitory effect on the AR activity at the 
highest concentration tested (12.5 mgplacenta/mL). However, six α-frac-
tions compromised cell viability at this concentration (# 1, 7, 8, 9, 12 
and 16), and three (# 2, 21 and 25) showed error bars slightly above the 
cut-off value. Consequently, 14 placentas were considered as positive for 
AR antagonism activity (Fig. 3.C) uniquely based on the cut-off criteria. 
Among the positives, about half of the placental fractions led to Emax 
values above 70 % of AR activity inhibition, with α-fractions # 10, 11, 
14, and 15 being among the most efficacious. If the criteria were based 
on the presence of a concentration-dependent response together with 
the presence of an average response below the cut-off value, 22 out of 
the 24 placental fractions would be classified as antiandrogenic. No 
compromised cell viability was observed at the lowest (1.25 mgplacenta/ 
mL) and medium (4.2 mgplacenta/mL) concentrations tested. 
3.3.3. Aryl hydrocarbon receptor (AhR) activity 
Although increases in AhR-transactivity were observed for placental 
α-fractions # 1, 8, 14, and 20, only placenta 14 was above the cut-off 
value (Fig. 3.D). Cell viability was compromised in α-fractions # 5, 8 
and 11 at the highest concentration tested (7.5 mgplacenta/mL). 
3.3.4. Thyroid activity 
Placental α-fractions # 5, 24 and 25 were not tested in this in vivo 
assay, due to lack of sample availability. The positive control group was 
exposed to triiodothyronine (T3) hormone at 5 nM. All data was 
normalized to vehicle control, which was normalized to 1, shown in 
continuous line (Fig. 4). 
The inhibition of the thyroid activity was consistent across all 
twenty-one α-fractions tested after 72 h of exposure (Fig. 4). All 
α-fractions, except # 8, 9, 15 and 23 induced a statistically significant 
decrease (p < 0.05) of the thyroid activity when compared with the 
positive control group. The highest antagonistic thyroid activity was 
shown for α-fractions # 1, 2, 12, 13, 14 and 20. 
Fig. 3. In vitro activity exerted by placental α-fractions determined by the estrogenic- proliferative effect (E-Screen), estrogen receptor (ER) transactivity, androgen 
receptor (AR) antagonism, and aryl hydrocarbon receptor (AhR) activity gene assays. (A) E-Screen data for placental α-fractions tested at 75 mgplacenta/mL, 150 
mgplacenta/mL and 750 mgplacenta/mL in duplicates in a single independent experiment. (B) ER transactivation assay data for placental α-fractions tested at 124 
mgplacenta/mL, 248 mgplacenta/mL, and 1240 mgplacenta/mL in duplicates in a single independent experiment. (C) AR antagonismt assay for placental α-fractions tested 
at 1.25 mgplacenta/mL, 4.2 mgplacenta/mL, and 12.5 mgplacenta/mL in triplicates in three independent experiments. (D) AhR reporter gene assay data for placental 
alpha-fractions tested at 0.75 mgplacenta/mL, 2.5 mgplacenta/mL, and 7.5 mgplacenta/mL in triplicates in two independent experiments. All graphs are presented as data 
normalized to vehicle controls (mean ± SD), set to 1 (continuous line). Graph C and D data were normalized in independent experiments and then mean values were 
pooled. Cut-off values are indicated with a dotted line. C = compromised cell viability/cell toxicity. Arrows highlight the maximum efficacy exerted by α-fractions. 
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3.4. General overview of bioassay activities 
A summary of the results obtained from the 5 bioassays is shown in 
Table 2. 
3.5. Correlations among bioassays 
Pearson correlation coefficients among bioassay activities are pre-
sented in Table 3. Additionally, the bioassay data taken as independent 
variable was categorized into tertiles to assess the shape of the corre-
lation among biological activities (Fig. 5). Overall, α-fraction 
concentrations showing no cytotoxicity and with the highest magnitude 
responses were selected to perform the correlation analyses. Thus, 
chosen concentrations were: 750 mgplacenta/mL for the E-Screen, 124 
mgplacenta/mL for the ER reporter gene assay, 4.2 mgplacenta/mL for the 
AR reporter gene assay and 2.5 mgplacenta/mL for the AhR reporter gene 
assay. For XETA, only one concentration was tested and, therefore used 
for the analysis. Notwithstanding, a correlation matrix among all 
bioassay dilutions that showed no cytotoxicity can be consulted in Table 
S3 of the Supplementary Material. 
The E-Screen assay activity showed a positive and significant cor-
relation with the ER reporter gene assay activity, and a positive 
borderline-significant correlation with the AR reporter gene assay ac-
tivity (Table 3). When the E-Screen was categorized into tertiles from 
lower to higher ER-mediated proliferative effect, a linear positive dose- 
response correlation was observed between responses in both estrogenic 
bioassays (Figs. 5.A and 5.C). 
The ER reporter gene assay activity showed a positive and significant 
correlation with the E-screen assay activity and a positive borderline- 
significant correlation with the AR reporter gene assay activity 
(Table 3). After categorizing the ER reporter gene assay into tertiles from 
the lowest to highest ER transactivity, only the correlation with the E- 
Screen assay showed a linear dose-response shape (Figs. 5.C and 5.D). 
The AR reporter gene assay activity showed a positive borderline- 
significant correlation with both, the E-Screen and the ER reporter 
assay activities (Table 3). When the AR reporter gene assay was cate-
gorized into tertiles from lower to higher AR antagonistic effect, results 
showed linear dose-response correlations for both the E-screen and the 
ER reporter gene assay activities (Figs. 5.E, and 5.F). In other words, a 
higher xenoestrogenicity tended to be correlated with a higher anti- 
androgenicity. 
The AhR reporter gene assay activity did not show any significant 
correlation with other bioassays (Table 3). After categorizing the AhR 
Table 2 
Effect of 24 placental α-fractions tested in the E-screen assay, the estrogen re-
ceptor (ER), androgen receptor (AR) and aryl hydrocarbon receptor (AhR) re-
porter gene assays, and the thyroid function assay (XETA). E-screen, ER and AhR 
assays were performed in agonist mode, whereas the AR reporter gene assays 
and XETA were performed in the antagonist mode.  
(Red, POS): the placental α-fraction affects activity above the cut-off value and is 
deemed positive, in the case of XETA, it was statistically significant when 
compared to control. (Blue, NEG): the placental α-fraction affects activity below 
the cut-off value and is deemed negative, in the case of XETA, it was not sta-
tistically significant when compared to control. (White, –): the placental 
α-fraction was not tested. 
Fig. 4. Antagonistic thyroid activity exerted by 
21 placental α-fractions tested in the Xenopus 
Embryo Thyroid-signaling Assay (XETA), after 
72 h of exposure. Samples were tested at a 
concentration equivalent to 187.5 mgplacenta/ 
mL in two independent experiments. Data was 
normalized to the negative control group (mean 
± SE), set to 1 (continuous line). SE = standard 
error. Each α-fraction was tested in two exper-
iments except for α-fractions 8, 9, 13 and 15. 
Samples 5, 24 and 25 were not tested due to 
lack of sample availability. *p < 0.05; **p <
0.01; ***p < 0.001; ****p < 0.0001. The arrow 
highlights the maximum efficacy exerted by 
α-fractions.   
Table 3 
Pearson correlation coefficients assessing the relationships among bioassays 












E-Screen (%) – 0.492* 0.347† − 0.103 − 0.058 
ER (%) 0.492* – 0.333† − 0.300 − 0.230 
AR antagonism (%) 0.347† 0.333† – 0.086 − 0.081 
AhR (%) − 0.103 − 0.300 0.086 – 0.009 
XETA antagonism (%) − 0.058 − 0.230 − 0.081 0.009 – 
Concentrations selected for the main analyses were: 750 mgplacenta/mL for the E- 
Screen; 124 mgplacenta/mL for the ER reporter gene assay; 4.2 mgplacenta/mL for 
the AR reporter gene assay; 2.5 mgplacenta/mL for the AhR reporter gene assay; 
and 1875 mgplacenta/mL for XETA. 
*p ≤ 0.05 † ≤ 0.10. 
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reporter gene assay into tertiles from lower to highest AhR activity, a 
linear dose-response correlation between AhR and ER activity was 
observed (Fig. 5.G). 
The XETA results were not correlated with any of the remaining 
bioassays (Table 3). Fig. 5.H shows a non-linear correlation between the 
ER reporter gene assay and XETA values categorized into tertiles 
(Fig. 5.H). 
In general, coefficients of determination (r2) in the regression models 
were modest (Fig. 5). 
4. Discussion 
4.1. Chemical mixtures interact with diverse signaling pathways 
In this screening study, HPLC α-fractions containing “real-world” 
mixtures of lipophilic and persistent chemicals were isolated from 24 
human placentas and tested in 5 different bioassays, in an effort to 
comprehensively address the biological effect of chemical mixtures on 
different biological endpoints. Overall, most placental fractions elicited 
estrogenic activities in both the E-Screen and the ER reporter gene assay. 
While 14 out of 24 placental α-fractions were clearly positive for anti- 
androgenic activity based on the cut-off value, most fractions (22 out 
of 24) were considered positive for AR inhibition when both a 
Fig. 5. Linear regression models categorizing the in-
dependent variable into tertiles from lower to higher 
signals obtained in each biomarker of combined activ-
ity. Data shown makes reference to significant or 
borderline-significant correlations found in Table 3, to 
test the functional shape of the correlations. (A) E- 
screen correlation with ER reporter gene assay; (B) E- 
Screen correlation with AR reporter gene assay; (C) ER 
gene reporter assay correlation with the E-Screen;(D) 
ER reporter gene assay correlation with AhR reporter 
gene assay; (E) AR reporter gene assay correlation with 
the E-Screen; (F) AR reporter gene assay correlation 
with the ER reporter gene assay; (G) AhR reporter gene 
assay correlation with the ER reporter gene assay;(H) 
XETA correlation with the ER reporter gene assay. Co-
efficients of determination (r2): 5.A: r2 = 0.202; 5.B: r2 
= 0.095; 5.C: r2 = 0.166; 5.D: r2 = 0.228; 5.E: r2 =
0.121; 5.F: r2 = 0.105; 5.G: r2 = 0.030; 5.H: r2 = 0.151.   
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concentration-dependent response as well as average responses below 
the cut-off were accounted for. Additionally, most placental α-fractions 
showed a clear inhibition of thyroid activity in the in vivo XETA, while 
subtle induction effects were noticed in the AhR gene assay. 
Differences in sensitivity across bioassays were noticed, since effects 
were observed at placental concentrations < 12.5 mgplacenta/mL in the 
AR reporter gene assay, whereas in the estrogen assays higher placental 
concentrations were needed to induce effects. However, the range of 
effects observed was higher in the E-Screen assay, which allowed to 
detect a wide variability among the α-fractions tested. Interestingly, 
when correlation analyses were conducted, the highest correlation was 
found between the two estrogenic bioassays, while a positive trend was 
observed between xeno-estrogenic and anti-androgenic activities. This is 
most likely due to the similar information reported by the E-Screen and 
the ER-reporter gene assay, since both of them evaluate the same 
signaling pathway. Additionally, the positive correlation observed be-
tween both estrogenic assays and the anti-androgenic assay is not un-
expected since compounds eliciting estrogenic activity often tend to 
behave as antiandrogens as previously shown, including a potential 
cross-talk between ER and AR signaling [40–43]. In addition, placental 
fractions with the highest estrogenicity also tended to show the lowest 
AhR activity, which could be due to the inhibitory cross-talk reported 
between AhR and ER [44]. The XETA results hardly correlated with any 
other selected bioassays, suggesting that this assay is responsive to 
chemical families whose biological effects may not be captured by the 
remaining assays. Despite the observed correlations among bioassays, r2 
coefficients were modest (Fig. 5), suggesting that the variance in bio-
logical activity was only partially predicted by the remaining assays, and 
that consequently, various bioassays are needed to characterize the ef-
fects of complex chemical mixtures. To the best of our knowledge, this 
study represents the first attempt to comprehensively map the biological 
effects of chemical mixtures present in the same human placental 
samples. 
4.2. Bioassays as biomarkers of combined effect in epidemiologic studies 
One of the potential applications of these bioassays is their use as 
biomarkers for characterizing the combined effect of chemical mixtures 
in human samples. Previous epidemiologic studies have tested the cu-
mulative estrogenic and anti-androgenic activities elicited by α-fractions 
extracted from placenta samples. For example, a nested case-control 
study within the Spanish INMA Granada mother-child cohort [27], re-
ported for the first time that children with a higher placental 
xeno-estrogenicity, assessed by the E-Screen, had higher risk to develop 
urogenital malformations: cryptorchidism and/or hypospadias [27]. 
Similarly, Arrebola et al. (2015), found that children with higher 
placental anti-androgenic activity had higher risk to develop the same 
urogenital malformations [20]. Interestingly, when comparing our re-
sults with the abovementioned studies that studied placenta samples 
collected years ago, the present screening study found similar estrogenic 
and anti-androgenic combined effects exerted by persistent chemical 
mixtures extracted from human placentas at similar magnitudes (Figs. 2. 
A and 2.C). Taken together, the observed biological activities suggest 
that unborn children are prenatally exposed to complex mixtures of 
chemicals that may exert potential harmful effects during this critical 
window of development. 
In a series of research studies from the Spanish INMA prospective 
birth cohort assessing placental α-fractions from different Spanish areas 
(Asturias, Gipuzkoa, Sabadell, Granada and Valencia), higher levels of 
xeno-estrogenicity were associated with increased birth weight [25], 
more behavioral problems in boys [24], as well as differences in 
genome-wide DNA methylation and repetitive elements [45,46]. Taken 
together, the combined estrogenic activity exerted by placental mixtures 
of lipophilic chemicals have been associated with several adverse health 
effects in children, supporting the utility of this approach for generating 
hypotheses between chemical mixtures and human health. 
Our current findings complement the abovementioned information, 
suggesting that bioassays related to different signalling pathways and 
specific receptor activities (e.g. XETA and AhR) may be needed to 
comprehensively characterize the whole biological fingerprint of expo-
sure to complex mixtures. For instance, our results showed that 
placental α-fractions induced a weak AhR activity, which could be due to 
the observed decreasing trends in exposure to dioxin and dioxin-like 
compounds in the Spanish population [47,48]. Moreover, dioxins pre-
sent in placental α-fractions could exert an anti-estrogenic activity, thus 
potentially explaining the not significant but inverse dose-response 
correlation observed between the AhR assay and the ER reporter gene 
assay, as previously suggested in other studies [49]. Although not in 
placenta samples, previous studies have used the AhR reporter gene 
assay in similar contexts (for a recent overview see [29]). In a 
case-control study using serum samples, higher POPs-induced AhR ac-
tivity was found in breast cancer cases compared to controls [14]. 
Another case-control study showed that the activity of the AhR elicited 
by amniotic fluid extracts was not associated with the risk of autism 
spectrum disorder (ASD) in children [50]. 
4.3. XETA as a potential novel biomarker of combined effect 
Few studies have tested the xeno-activity of mixtures on the thyroid 
axis [51,52]; furthermore, the XETA has not been used before to assess 
the effect of chemical mixtures isolated from human samples. Moreover, 
there are no validated in vitro assays to assess thyroid disruption, and in 
contrast to the previous endocrine modalities tested, the XETA may 
detect endocrine disruption arising from multiple levels of regulation 
[53,54]. In the present screening study, placental α-fractions showed a 
strong inhibition of thyroid signaling, in line with previous anti-thyroid 
effects exerted by chemicals mixtures made ad hoc based on human 
amniotic fluid exposure levels [55]. While ad hoc mixtures can only test 
previously known chemicals, extraction protocols in human samples 
coupled to bioassays are able to assess biological activities of “real--
world” mixtures with both known and unknown environmental chem-
icals. In the current study, the XETA was not correlated with any other 
implemented bioassays, suggesting that the observed anti-thyroid ac-
tivity was not related to the remaining biological activities. On the one 
hand, this is in line with thyroid receptors not being structurally related 
to steroid hormone receptors. On the other hand, the XETA in vivo assay 
presents a higher level of biological complexity compared to in vitro 
models, and observed effects may be driven by diverse action mecha-
nisms not limited to the receptor level of the 
hypothalamus-pituitary-thyroid axis. XETA results highlight that 
different biomarkers of combined activity, representing different 
signaling pathways, should be used to fully characterize the cumulative 
effects elicited by complex chemical mixtures in human populations. 
The XETA has been recently validated at the OECD level (TG248) as a 
Tier 3 assay [37], and our findings highlight it as a promising biomarker 
of combined anti-thyroid effect which should be further investigated in 
population-based studies, particularly in relation to neurological 
endpoints. 
4.4. Identification of the chemicals responsible for biological effects 
Sample preparation and extraction is critically important, especially 
when investigating environmental chemicals in human samples. As 
extraction methods are rarely optimized for bioassays but rather adop-
ted from chemical analysis, this may result in a misrepresentation of the 
actual biological activity [15]. HPLC α-fractions obtained from human 
samples allows the assessment of the combined effects elicited by the 
most lipophilic and persistent compounds while avoiding the interfer-
ence of endogenous hormones [26,56,57]. As previously reported, if the 
endogenous hormones are present in the mixture, they can saturate the 
endpoint of the in vitro or in vivo assay. Thus, the biological activity of 
chemical mixtures would be importantly masked, leading to a reduction 
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in the variability of the signal elicited as well as an underestimation of 
the combined effect [32,58]. This is not the case with the extraction 
protocol used. Several studies have demonstrated the absence of 
endogenous steroid hormones and identified some chemical families 
present in the α-fraction: mainly lipophilic and persistent organic pol-
lutants (POPs) such as polychlorinated biphenyls (PCBs) and organo-
chlorine pesticides (OCPs), including lindane, hexachlorobenzene 
(HCB), dichlorodiphenyltrichloroethane (DDT) and dichlor-
odiphenyldichloroethylene (DDE), among others [14,27,57,59]. The 
chemical compounds detected by previous studies in the α-fraction are 
listed in Supplemental Table 1. 
Although some chemical groups have been identified in α-fractions, 
its full chemical composition has not been elucidated yet, and the 
number of chemical families and metabolites contained is anticipated to 
be much higher. A step forward for both environmental toxicology and 
epidemiology would be the identification of those chemical compounds 
responsible of such biological effects, including the characterization of 
both unknown and emerging contaminants. In this regard, it has been 
proposed that non-targeted chemical analyses can help to decipher the 
chemical composition of complex lipophilic mixtures isolated from 
human samples [60]. Indeed, suspect and non-target methodologies are 
being developed inside the HBM4EU project [61]. Interestingly, effect 
directed analysis (EDA) coupled with non-target chemical analysis can 
be used to overcome some limitations, allowing an efficient identifica-
tion of biologically active chemicals through sub-fractionation pro-
cesses, thus facilitating non-target chemical analysis [62]. Further 
research is ongoing using EDA coupled to non-targeted chemical anal-
ysis on these placental α-fractions in order to characterize the bioactive 
chemicals responsible for the observed combined biological activities. 
4.5. Strengths and limitations 
A major strength of this study is the application of five different 
biological assays on the same set of human placentas, mapping different 
signaling pathways and exploring their relationships. Additionally, this 
is the first study which has assessed human samples with the in vivo 
XETA, showing a clear anti-thyroid activity, which adds valuable in-
formation regarding the effect of lipophilic environmental contaminants 
on this important pathway. Finally, this is the first attempt to correlate 
various biological activities exerted by the same mixture of lipophilic 
compounds extracted from human samples in order to explore potential 
relationships among them. This study also presents some limitations. 
The relatively small number of placenta samples analyzed limited our 
ability to observe correlations among bioassays. Although the α-fraction 
provides a good representation of the most lipophilic and persistent 
compounds, the full chemical exposome was not addressed. In addition 
to the known chemical families previously detected in the α-fraction, 
non-targeted chemical methodologies will be needed to unravel its 
complex chemical composition. Another limitation is that the tested 
biological assays do not measure the biological effects elicited by mix-
tures of lipophilic compounds at the same levels of biological 
complexity. For instance, the in vivo XETA evaluated the highest level of 
biological complexity; the E-screen assessed cell proliferation after 6 
days of exposure; and the reporter gene assays tested the ability of the 
mixture to agonize or antagonize a particular nuclear receptor. These 
disparities and other methodological differences (e.g. different di-
lutions, medium for reconstitution of dried extracts, etc.) should be 
considered when interpreting the results of this screening study. Finally, 
the centralized isolation of α-fractions in the same laboratory under 
controlled conditions (e.g. glassware material, work inside flow- 
chambers) limited potential background contamination. These mea-
sures, together with the strong and variable biological activities 
observed for most -but not all- of the placentas in the selected bioassays 
(estrogenic, anti-androgenic, anti-thyroid and AhR activities), and at 
different dilutions, makes unlikely that results could be explained in 
terms of sporadic background contamination. 
This work represents a multidisciplinary effort to evaluate human 
exposure to chemical mixtures by synergizing the toxicological and 
epidemiological fields. Isolation and assessment of chemical mixtures 
from human samples may help to identify bioactive chemicals respon-
sible for a given biological activity, as well as identify novel bioactive 
chemicals through complementary methodologies. In parallel, a battery 
of in vitro and in vivo bioassays should play a crucial role in the assess-
ment of human exposure to complex mixtures, since they can determine 
the joint activity elicited by complex mixtures through a specific mode 
of action [52]. The use of this combined approach together with the 
information provided by additional biomarkers of effect (e.g. hormone 
levels, biochemical parameters, etc.) would help to strengthen the 
weight of evidence in observational studies linking chemical exposures 
to health outcomes. 
5. Conclusions 
A panel of different bioassays is needed to provide a comprehensive 
assessment of “real-world” chemical mixtures. The biomarkers of com-
bined activity investigated in this work enabled us to better characterize 
the signaling pathways through which mixtures could elicit adverse 
health outcomes in humans. Epidemiological studies should also include 
these bioassays as a complementary tool to improve the causal inference 
of exposure-effects relationships in the context of complex mixtures. 
Further research is needed to characterize the full composition of 
complex chemical mixtures present in human samples. 
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